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I 
n the last few years, our understanding of the mechanisms 
￿9  involved in the interaction between major histocompati- 
bility complex (MHC) class II molecules and antigenic pep- 
tides has greatly increased. The determination of the x-ray 
structure of a human class II molecule (1, 2), the selection 
of large, class II-bound, peptide repertoires using M13 pep- 
tide display libraries  (3, 4), and the characterization of class 
II-eluted, naturally processed peptides (5-9) has elucidated 
the structural requirements for peptide binding to class II 
molecules. 
The peptide binding groove of class II molecules is open 
at both ends (1, 2),  thus allowing class II-bound peptides 
to extend beyond both termini. As a result, these peptides 
are longer than those bound by class I molecules and exhibit 
considerable length variation, typically 12-24 residues (5-9). 
Class II molecules form many conserved hydrogen bonds with 
the peptide main chain, thus forcing class II-bound peptides 
into a similar conformation despite differences in their pri- 
mary sequence. In addition, class II molecules make several 
contacts with peptide side chains to increase the overall binding 
affinity of the bound peptides. Side chain contacts differ be- 
tween different alleles, and determine the peptide sequence 
specificity or "motif" for each class II allele. Recently, the 
motifs of various human class II (DR) molecules have been 
identified by the characterization of large, DR-bound pep- 
tide pools selected from M13 peptide display libraries (4, 10). 
These motifs consist of several peptide positions where amino 
acids with similar side chains occur with increased frequen- 
cies (anchor positions). 
The anchor position closest to the NH2-terminus (anchor 
position 1) is essential for a high affinity interaction between 
peptides and all DR molecules tested so far. The position 
1 anchor accepts only aromatic or large aliphatic peptide side 
chains that interact with a deep pocket in the DR binding 
groove, built by both the invariant DR o~-chain and a fairly 
conserved part of the DR 3-chain (1, 2). Other major, but 
less essential, anchor positions are found at peptide positions 
4, 6,  and 9.  The peptide side chains in these positions in- 
teract with shallow pockets shaped by clusters ofpolymorphic 
residues of the DR B-chain and determine allele-specific pep- 
tide binding. 
Of similar importance for peptide-class II interaction is 
the presence or absence of peptide side chains which can in- 
terfere with peptide binding (inhibitory residues).  Studies on 
designer peptide libraries and natural peptide sequences have 
indicated both position- and allele-specific properties of in- 
hibitory residues (10-13).  Interestingly, inhibitory residues 
are found more frequently at anchor positions,  since these 
are the major contact sites for the peptide side chains with 
the class II molecule. The capacity of a given peptide to bind 
a certain MHC class II molecule therefore, is the result of 
attracting and repelling forces between peptide side chains 
and residues lining the MHC binding site. 
Several promiscuous peptides, capable of binding to many 
different class II alleles, have been identified (14-16).  Promis- 
cuous peptides  should  either contain  overlapping class  II 
binding motifs or, in case only one binding flame is used, 
they should use anchors that are conserved among DR ligands 
and should lack allele-specific contact sites that could prevent 
binding to other class II molecules. Such a "supermotif' has 
now been found both by Malcherek et al. (17) and Sette et 
al. (18) in the class II-associated invariant chain peptide (CLIP) 
described in this issue of The  Journal of  Experimental Medicine. 
The invariant chain (Ii) has an important role in the regu- 
lation and function of class II molecules (19).  It promotes 
effective association and folding of class II ot and B subunits, 
induces their transport out of the endoplasmic reticulum, and 
inhibits class II peptide binding before entry into endosomal 
compartments. The ability of Ii to interact with class II and 
interfere with peptide loading has been mapped to Ii exon 
3, which encodes amino acids 83-107 corresponding to the 
CLIP peptide (20).  In principle, CLIP could bind,  as part 
of Ii,  to a conserved site of the class II molecule, altering 
its conformation and therefore preventing the binding of an- 
tigenic peptides, or it could behave as a promiscuous peptide 
by binding directly to the peptide binding sites of different 
class II alleles. 
The two papers by Malcherek et al. (17) and Sette et al. 
(18) of this issue indicate that CLIP indeed possesses the char- 
acteristics of a promiscuous peptide binding the class II binding 
groove (Fig.  1). By synthetic peptide chemistry, Malcherek 
et al. (17) demonstrated that CLIP uses the same peptide frame 
to bind to the grooves of the two very different class II mole- 
cules,  DRBI*0101  and DRBI*0301  (21, 22).  CLIP uses a 
methionine as position 1 anchor. The usage of an aliphatic 
rather than an aromatic residue at the first anchor position 
allows  CLIP to bind to all DR alleles independent of the 
polymorphic 86 position of the DR/~ chain, which excludes 
large aromatic residues (Tyr and Trp) in some DR alleles (12, 
23).  Malcherek et al.  (17) further indicate that CLIP lacks 
particular allele-specific contact sites at the major anchor and 
inhibitory positions 4 and 6 (Fig.  1). Indeed, Ala94 at posi- 
tion 4  and Pro96 at position 6 appear to be fairly well ac- 
cepted by all DR alleles tested so far (24).  With the excep- 
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Figure  1.  Anchor  and inhibitory  residue  positions  in the CLIP  peptide. 
tion of the Arg92 at relative  position 2 (Fig.  1),  CLIP has 
also avoided  charged and large aromatic residues.  There is 
sufficient evidence that both types of amino acids can inter- 
fere with peptide-binding to many class II molecules (10, 13). 
Thus, CLIP appears to have evolved as a promiscuous pep- 
tide by using a position I anchor and side chains in positions 
2-9 which are  generally accepted  by all DR alleles. 
The fact, however, that CLIP uses some allele-specific an- 
chor residues,  e.g., Met at position 9 for DR1 or Arg and 
Leu at positions 2 and 7 for DRBI*0401 (Fig.  1), support 
data from Sette et al. (18) showing major variations in the 
binding affinity of CLIP to different class II molecules.  Fur- 
thermore, a better understanding of the peptide motifs rec- 
ognized by DQ and DP molecules is necessary to generalize 
Malcherek's observation. In conclusion, Malcherek et al. (17) 
and Sette et al. (18) provide compelling, although not abso- 
lutely conclusive proof, that CLIP is indeed a universal class 
II ligand in accordance with the emerging principles  of pep- 
tide-class  II  interaction.  It needs  to be  shown,  however, 
whether CLIP binds in a promiscuous mode also when it is 
part of the Ii chain and whether other Ii regions, besides 
CLIP, play a  role in  its  interaction with  the  class II  a~ 
dimer (20). 
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